Success and tolerability of DVI.
One hundred four of 106 participants aged 6 months to 61 years were administered study product by DVI: 80 participants received 223 doses of PfSPZ Vaccine by DVI, and 24 participants received 69 doses of NS (CONSORT diagram—study enrollment, group allocation, and analysis populations. CVac = non-attenuated PfSPZ attenuated in vivo by coadministration of chloroquine; NS = normal saline; PfSPZ = 